...
首页> 外文期刊>The Biochemical Journal >A novel strategy for the development of selective active-site inhibitors of the protein tyrosine phosphatase-like proteins islet-cell antigen 512 (IA-2) and phogrin (IA-2 beta)
【24h】

A novel strategy for the development of selective active-site inhibitors of the protein tyrosine phosphatase-like proteins islet-cell antigen 512 (IA-2) and phogrin (IA-2 beta)

机译:开发蛋白质酪氨酸磷酸酶样蛋白胰岛细胞抗原512(IA-2)和凝集素(IA-2 beta)的选择性活性位点抑制剂的新策略

获取原文
获取原文并翻译 | 示例
           

摘要

Islet-cell antigen 512 (IA-2) and phogrin (IA-2) are atypical members of he receptor protein tyrosine phosphatase (PTP) family that are characterized by a lack of activity against conventional PTP substrates. The physiological role(s) of these proteins remain poorly defined, although recent studies indicate that IA-2 may be involved in granule trafficking and exocytosis. To further 9 understand their function, we have embarked upon developing low-molecular-mass inhibitors of IA-2 and IA-2. Previously, we have shown that a general PTP inhibitor, 2-(oxalylamino)benzoic acid (OBA), can be developed into highly selective and potent inhibitors of PTP1B. However. since wild-type IA-2 and IA-2beta lack conventional PTP activity, a novel strategy was designed whereby catalytically active species were generated by 'back-mutating key non-consensus catalytic region residues to those of PTP1B. These mutants were then used as tools with which to test the potency and selectivity of OBA and a variety of its derivatives. Catalytically competent IA-2 and IA-2beta species were generated by 'back-mutation' of only three key residues (equivalent to Tyr(46). Asp(181) and Ala(217) using the human PTP1B numbering) to those of PTP1B. Importantly, enzyme kinetic analyses indicated that the overall fold of both mutant and wild-type IA-2 and IA-2beta was similar to that of classic PTPs. In particular, one derivative of OBA, namely 7-(1,1-dioxo-1H-benzo[d]isothiazol-3-yloxy-methyl) -2-(oxalylamino)-4,7-dihydro-5H-thieno [2,3-c] pyran-3-carboxylic acid ('Compound 6' shown in the main paper), which inhibited IA-2beta((S762Y/Y898P/D933A)) (IA-2beta in which Ser(762) has been mutated to tyrosine, Tyr(898) to proline, and Asp(933) to alanine) with a K-i value of approximate to 8 muM, appeared ideal for future lead optimization. Thus molecular modelling of this classical, competitive inhibitor in the catalytic site of wild-type IA-2beta identified two residues (Ser(762) and ASP(933)) that offer the possibility for unique interaction with an appropriately modified 'Compound 6'. Such a compound has the potential to be a highly selective and potent active-site inhibitor of wild-type IA-2beta. [References: 32]
机译:胰岛细胞抗原512(IA-2)和凝集素(IA-2)是受体蛋白酪氨酸磷酸酶(PTP)家族的非典型成员,其特征是缺乏针对常规PTP底物的活性。尽管最近的研究表明IA-2可能参与了颗粒运输和胞吐作用,但这些蛋白质的生理作用仍然不清楚。为了进一步了解9的功能,我们着手开发IA-2和IA-2的低分子抑制剂。以前,我们已经表明,一般的PTP抑制剂2-(草酰氨基)苯甲酸(OBA)可以发展成为高度选择性和有效的PTP1B抑制剂。然而。由于野生型IA-2和IA-2beta缺乏常规的PTP活性,因此设计了一种新的策略,即通过将关键的非共有催化区域残基反向突变为PTP1B的残基来产生催化活性物质。然后将这些突变体用作测试OBA及其各种衍生物的效能和选择性的工具。具有催化活性的IA-2和IA-2beta物种是通过仅对三个关键残基(使用人PTP1B编号相当于Tyr(46),Asp(181)和Ala(217))进行“反向突变”而生成的。 。重要的是,酶动力学分析表明,突变型和野生型IA-2和IA-2beta的总体折叠与经典PTP相似。特别是,OBA的一种衍生物,即7-(1,1-二氧代-1H-苯并[d]异噻唑-3-基氧基-甲基)-2-(草酰氨基)-4,7-二氢-5H-噻吩并[2 ,3-c]吡喃-3-甲酸(在主文件中显示为“化合物6”),可抑制IA-2beta((S762Y / Y898P / D933A))(其中Ser(762)发生突变的IA-2beta Ki值接近8μM的酪氨酸,Tyr(898)脯氨酸和Asp(933)丙氨酸)似乎是未来铅优化的理想选择。因此,这种经典的竞争性抑制剂在野生型IA-2beta催化位点的分子模型确定了两个残基(Ser(762)和ASP(933)),为与适当修饰的“化合物6”进行独特相互作用提供了可能性。这样的化合物具有成为野生型IA-2beta的高选择性和有效活性位点抑制剂的潜力。 [参考:32]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号